Nanotechnology Perceptions
ISSN 1660-6795
www.nano-ntp.com

Thyroid Dysfunction Among Patients with Chronic Kidney Disease

Abdelkader Ahmed Hashim Mohamed[1], Ali Taha Ali Elkoriaty[2], Wael Hagag Ahmed[3], Shimaa Fathy Sakr[4], Mohammed H Hassan[5]

[1]Associate Professor of Internal Medicine And Nephrology (South Valley University)
[2]Professor Of Internal Medicine And Nephrology (Sohag University)
[3]Assistant fellow of internal medicine, Sohag teaching hospital
[4]Molecular Biology Unit, Medical Technology Center (Medical Research Institute, Alexandria University)
[5]Professor Of Medical Biochemistry (South Valley University)

Thyroid dysfunction is a prevalent but often underrecognized complication among patients with chronic kidney disease (CKD). The altered thyroid hormone metabolism in CKD patients can complicate the diagnosis and management of both diseases, contributing to poor clinical outcomes. This review aims to summarize the current understanding of thyroid dysfunction in CKD, including its pathophysiology, clinical manifestations, diagnostic challenges, and management strategies.

Keywords: Thyroid dysfunction, Chronic kidney disease (CKD), Hypothyroidism, Subclinical hypothyroidism, Euthyroid sick syndrome (ESS), End-stage renal disease (ESRD), Thyroid hormone metabolism, Uremic toxins, Thyroid function tests

1. Introduction

Chronic kidney disease (CKD) is a global health problem that affects millions of individuals worldwide. CKD is associated with several comorbidities, including cardiovascular disease, diabetes, and endocrine disorders, particularly thyroid dysfunction. Thyroid abnormalities in CKD patients are common, with hypothyroidism, subclinical hypothyroidism, and euthyroid sick syndrome (ESS) being the most frequently encountered. These thyroid disorders can complicate the management of CKD, influence disease progression, and impact the quality of life of affected patients.(1)

Thyroid dysfunction is a relatively common occurrence among patients with chronic kidney

disease (CKD). The relationship between thyroid function and kidney disease is complex, and abnormalities in thyroid function can exacerbate the clinical course of CKD. There are several mechanisms and implications of thyroid dysfunction in CKD patients, including both hypothyroidism and hyperthyroidism.(2)

While the relationship between thyroid function and kidney disease has been recognized for decades, the pathophysiology remains complex, and thyroid dysfunction in CKD is often underdiagnosed. This review aims to provide a comprehensive overview of thyroid dysfunction in CKD patients, including its prevalence, mechanisms, diagnostic challenges, clinical implications, and management.(3)

Types of Thyroid Dysfunction in CKD

1. Hypothyroidism:

Hypothyroidism is more commonly observed in CKD patients. Several factors contribute to this, including:(4)

o Decreased renal clearance of thyroid hormones: CKD reduces the kidneys' ability to clear thyroid hormones, leading to increased levels of thyroid hormone-binding proteins, such as thyroxine-binding globulin (TBG).

o Reduced peripheral conversion of T4 to T3: The kidneys play a role in converting T4 (thyroxine) to T3 (triiodothyronine), the more active form of thyroid hormone. CKD can impair this conversion, leading to lower levels of T3.

o Uremic toxins: Uremic toxins in CKD can alter thyroid hormone metabolism and interfere with thyroid function.

o Comorbidities: Many CKD patients have comorbid conditions, such as diabetes, cardiovascular disease, or autoimmune diseases (e.g., Hashimoto's thyroiditis), which can also contribute to hypothyroidism.(5)

2. Subclinical Hypothyroidism:

Subclinical hypothyroidism (elevated TSH with normal T3 and T4 levels) is common in CKD, especially in stages 3–5. This condition may not exhibit overt symptoms, but it could potentially affect the patient's quality of life and contribute to other complications.(6)

3. Hyperthyroidism:

Hyperthyroidism is less common but can occur in CKD patients. Potential causes include:(7)

o Thyroiditis: Inflammation of the thyroid gland can lead to hyperthyroidism.

o Autonomic dysfunction: Autonomic nerve dysfunction, which is common in CKD, may contribute to thyroid dysfunction.

o Thyroid nodules: Multinodular goiter or solitary toxic nodules can also lead to hyperthyroidism, though this is less frequent in CKD.(8)

4. Euthyroid Sick Syndrome (ESS):

Euthyroid sick syndrome (also known as non-thyroidal illness syndrome) is a condition in

which thyroid function tests (e.g., low T3 levels) are abnormal due to illness or metabolic disturbances without any intrinsic thyroid disease. This is commonly observed in CKD, particularly in end-stage renal disease (ESRD), and is thought to be a response to systemic illness, inflammation, and metabolic stress associated with CKD.(9)

Prevalence of Thyroid Dysfunction in CKD

The prevalence of thyroid dysfunction in CKD is higher than in the general population. Various studies have reported that:(10)

1. Hypothyroidism:

Hypothyroidism is the most common thyroid disorder in CKD, with its prevalence increasing as kidney function declines. In the general population, hypothyroidism affects approximately 4-5% of individuals, while in CKD patients, the prevalence may range from 10% to 30%, depending on the stage of the disease. In end-stage renal disease (ESRD), the prevalence can exceed 40%.

2. Subclinical Hypothyroidism:

Subclinical hypothyroidism (elevated TSH with normal free T4 and T3 levels) is frequently observed in CKD, especially in stages 3–5. It is more common in elderly patients and those with coexisting conditions such as diabetes or hypertension.

3. Euthyroid Sick Syndrome (ESS):

Euthyroid sick syndrome, characterized by low T3 levels with normal TSH and T4, is frequently seen in patients with ESRD and uremia. The incidence of ESS increases with the severity of kidney dysfunction and is considered a physiological response to systemic illness, including kidney failure.

4. Hyperthyroidism:

Hyperthyroidism is less common in CKD patients but can occur due to conditions like thyroiditis, toxic multinodular goiter, or Graves' disease. However, hyperthyroidism is relatively rare compared to hypothyroid conditions in CKD.(11)

Mechanisms of Thyroid Dysfunction in CKD

The relationship between CKD and thyroid dysfunction is multifactorial, involving altered thyroid hormone metabolism, kidney function, and systemic inflammation.(12)

1. Altered Thyroid Hormone Metabolism:

The kidneys play a critical role in the conversion of T4 to T3, the active form of thyroid hormone. In CKD, there is a reduced activity of type 1 deiodinase, the enzyme responsible for this conversion, leading to low T3 levels despite normal or elevated T4 levels. This is particularly pronounced in uremia and is a key feature of euthyroid sick syndrome.

2. Uremic Toxins:

Uremic toxins, which accumulate in patients with declining kidney function, can impair thyroid hormone synthesis and metabolism. These toxins inhibit the deiodinase enzymes, contributing to a decrease in the conversion of T4 to T3 and possibly leading to elevated levels

of reverse T3 (rT3).

3. Altered Protein Binding:

CKD leads to changes in thyroid hormone-binding proteins, such as thyroxine-binding globulin (TBG). Reduced renal clearance of these proteins can lead to falsely elevated levels of total T4, although the free T4 and free T3 may remain normal or reduced.

4. Inflammatory Cytokines:

Chronic inflammation, which is common in CKD, can also disrupt thyroid function. Elevated levels of inflammatory cytokines, such as interleukin-6 (IL-6), can suppress the hypothalamic-pituitary-thyroid axis, reducing the production of thyroid hormones. This may lead to low T3 syndrome or subclinical hypothyroidism.

5. Medications:

Certain medications used in the treatment of CKD, including steroids, angiotensin-converting enzyme (ACE) inhibitors, and calcium channel blockers, can also affect thyroid hormone metabolism.(13)

Clinical Implications of Thyroid Dysfunction in CKD

1. Cardiovascular Risk:

Both hypothyroidism and hyperthyroidism have been linked to increased cardiovascular risk. In CKD, hypothyroidism is associated with increased risk of atherosclerosis, left ventricular hypertrophy, and heart failure. Hyperthyroidism, though rare in CKD, can contribute to arrhythmias, including atrial fibrillation, and may exacerbate heart failure.

2. Renal Function:

Thyroid dysfunction can influence kidney function. Hypothyroidism may reduce renal blood flow and glomerular filtration rate (GFR), while hyperthyroidism can cause hyperdynamic circulation and lead to worsening renal function, particularly in patients with pre-existing renal disease.

3. Quality of Life:

Symptoms of thyroid dysfunction, such as fatigue, weight changes, and depression, often overlap with those of CKD, leading to a poor quality of life. Correcting thyroid dysfunction can improve both physical and mental well-being in CKD patients.(14)

Diagnosis and Management of Thyroid Dysfunction in CKD

1. Diagnosis:

Diagnosis of thyroid dysfunction in CKD is primarily based on serum thyroid function tests, including TSH, free T4, and T3. However, in CKD, interpretation can be challenging due to altered protein binding and impaired T4 to T3 conversion. The presence of low T3 levels in the setting of normal TSH and T4 levels may suggest euthyroid sick syndrome, particularly in patients with ESRD.(15)

It is important to assess clinical symptoms in conjunction with thyroid function tests. If thyroid

dysfunction is suspected, further testing, such as antithyroid antibodies or neck ultrasound, may be necessary, particularly in cases of suspected autoimmune thyroid disease.(16)

2. Management of Hypothyroidism:

Levothyroxine therapy is the cornerstone of hypothyroidism treatment. However, in CKD, especially in patients with advanced stages, careful dosing is required due to altered pharmacokinetics. Close monitoring of thyroid function is necessary to avoid both overtreatment and undertreatment. Starting with lower doses and gradual titration is recommended, especially in elderly or dialysis patients.(17)

3. Management of Hyperthyroidism:

Treatment of hyperthyroidism in CKD follows standard protocols, including antithyroid drugs (e.g., methimazole), radioactive iodine therapy, or surgical resection. However, renal function must be considered when choosing the treatment modality.

4. Management of Euthyroid Sick Syndrome:

Euthyroid sick syndrome typically resolves with the improvement of the underlying illness. Thyroid hormone replacement is generally not recommended unless there is an underlying thyroid disease. Management should focus on optimizing renal function and addressing systemic inflammation.(18)

Thyroid dysfunction is common in CKD and can exacerbate the course of kidney disease. Both hypothyroidism and hyperthyroidism can occur, as well as euthyroid sick syndrome, complicating diagnosis and treatment. Given the overlap in symptoms between CKD and thyroid dysfunction, it is important to regularly assess thyroid function in CKD patients, especially those with advanced stages of kidney disease or those on dialysis. Treatment should be tailored to the patient's specific needs, and monitoring should be ongoing to avoid complications related to thyroid dysfunction.(19)

Chronic kidney disease (CKD) is a significant public health concern, affecting millions of people worldwide. CKD is associated with multiple comorbidities, including cardiovascular disease, diabetes, and thyroid dysfunction. Recent studies suggest a strong relationship between CKD and thyroid abnormalities, with hypothyroidism being particularly common in patients with advanced stages of kidney disease. However, the complex interplay between thyroid hormones and kidney function is not fully understood.(20)

The thyroid gland plays a critical role in regulating metabolism, growth, and development, with thyroid hormones exerting effects on virtually every organ system. In patients with CKD, abnormalities in thyroid hormone levels can complicate the management of the disease and contribute to poor clinical outcomes. This review aims to provide a comprehensive overview of the prevalence, mechanisms, clinical implications, and management of thyroid dysfunction in CKD.(21)

Hypothyroidism is the most frequently observed thyroid disorder in CKD. It is estimated that the prevalence of hypothyroidism in CKD ranges from 10% to 30%, with higher rates observed in patients with advanced stages (stage 4 and stage 5) of CKD. The prevalence may be even higher in patients undergoing hemodialysis, reaching up to 40%. Subclinical hypothyroidism,

defined by elevated thyroid-stimulating hormone (TSH) levels with normal free thyroxine (FT4) levels, is also common in CKD, particularly in patients with stage 3 or higher disease.(22)

Thyroid dysfunction is common in patients with CKD, and its presence can have significant clinical implications, including worsened cardiovascular outcomes, accelerated progression of renal disease, and impaired quality of life. The mechanisms underlying thyroid dysfunction in CKD are multifactorial, involving impaired renal clearance, altered thyroid hormone metabolism, and the influence of comorbidities. Diagnosis and management of thyroid dysfunction in CKD require careful interpretation of thyroid function tests and individualized treatment plans. Further research is needed to better understand the pathophysiology of thyroid dysfunction in CKD and to establish evidence-based guidelines for its management.(23)

2. Conclusion

Thyroid dysfunction is common in patients with CKD and has important clinical implications. Early identification and appropriate management of thyroid abnormalities can improve both the prognosis of CKD and the quality of life of affected individuals. The relationship between thyroid dysfunction and CKD remains complex, and further research is needed to elucidate the underlying mechanisms and to establish evidence-based guidelines for the management of thyroid dysfunction in CKD patients. Regular screening and monitoring of thyroid function should be considered in CKD patients, particularly those in the later stages of the disease or those undergoing dialysis.

References

1. Bednarczuk T, Brix TH, Schima W, Zettinig G, Kahaly GJ. 2021 European Thyroid Association guidelines for the management of iodine-based contrast media-induced thyroid dysfunction. Eur Thyroid J. 2021;10(4):269–84.
2. Paschou SA, Bletsa E, Stampouloglou PK, Tsigkou V, Valatsou A, Stefanaki K, et al. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75(3):672–83.
3. Chen SI, Chiang CL, Chao CT, Chiang CK, Huang JW. Gustatory dysfunction is closely associated with frailty in patients with chronic kidney disease. J Ren Nutr. 2021;31(1):49–56.
4. Alisherovna KM, Jamshedovna KD, Totlibayevich YS, Xudoyberdiyevich GX. FEATURES OF THE QUALITY OF LIFE OF PATIENTS WITH CHRONIC RENAL FAILURE IN THE TREATMENT OF HEMODIALYSIS. Spectr J Innov Reforms Dev. 2022;7:76–81.
5. Zikiryayevna SG, Zohirovna MG, Muxtorovna EM, Bahromovich SS. Kidney Damage in Patients with Chronic Cardiac Insufficiency and Obesity. Texas J Med Sci. 2022;13:72–8.
6. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, et al. Increased risk of thyroid dysfunction by PD-1 and CTLA-4 blockade in patients without thyroid autoantibodies at baseline. J Clin Endocrinol Metab. 2022;107(4):e1620–30.
7. Ruszkowski J, Heleniak Z, Król E, Tarasewicz A, Witkowski JM, Debska-Slizien A. Associations between symptoms of constipation and sleep quality in patients with nondialysis chronic kidney disease: A cross-sectional study. Pol Arch Intern Med. 2021;131:512–9.
8. Fu Z, Geng X, Chi K, Song C, Wu D, Liu C, et al. Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis. Ann Palliat Med. 2021;10(7):7427439–8439.
9. Wańkowicz P, Szylińska A, Rotter I. The impact of the COVID-19 pandemic on psychological health and insomnia among people with chronic diseases. J Clin Med. 2021;10(6):1206.

10. Gosmanova EO, Houillier P, Rejnmark L, Marelli C, Bilezikian JP. Renal complications in patients with chronic hypoparathyroidism on conventional therapy: a systematic literature review: renal disease in chronic hypoparathyroidism. Rev Endocr Metab Disord. 2021;22(2):297–316.
11. Joseph B, Nunez NA, Pazdernik V, Kumar R, Pahwa M, Ercis M, et al. Long-term lithium therapy and thyroid disorders in bipolar disorder: a historical cohort study. Brain Sci. 2023;13(1):133.
12. Baldelli R, Nicastri E, Petrosillo N, Marchioni L, Gubbiotti A, Sperduti I, et al. Thyroid dysfunction in COVID-19 patients. J Endocrinol Invest. 2021;44(12):2735–9.
13. Gosmanova EO, Chen K, Rejnmark L, Mu F, Swallow E, Briggs A, et al. Risk of chronic kidney disease and estimated glomerular filtration rate decline in patients with chronic hypoparathyroidism: a retrospective cohort study. Adv Ther. 2021;38:1876–88.
14. Evenepoel P, Cunningham J, Ferrari S, Haarhaus M, Javaid MK, Lafage-Proust MH, et al. European Consensus Statement on the diagnosis and management of osteoporosis in chronic kidney disease stages G4–G5D. Nephrol Dial Transplant. 2021;36(1):42–59.
15. Kim K, Song SH, Kim IJ, Jeon YK. Is dual-energy absorptiometry accurate in the assessment of bone status of patients with chronic kidney disease? Osteoporos Int. 2021;32:1859–68.
16. Xing Y, Yang L, Liu J, Ma H. The association with subclinical thyroid dysfunction and uric acid. Int J Endocrinol. 2021;2021(1):9720618.
17. Van Vliet NA, Van Heemst D, Almeida OP, Åsvold BO, Aubert CE, Bae J Bin, et al. Association of thyroid dysfunction with cognitive function: an individual participant data analysis. JAMA Intern Med. 2021;181(11):1440–50.
18. Jabbar A, Ingoe L, Thomas H, Carey P, Junejo S, Addison C, et al. Prevalence, predictors and outcomes of thyroid dysfunction in patients with acute myocardial infarction: the ThyrAMI-1 study. J Endocrinol Invest. 2021;44:1209–18.
19. Giovanella L, Ruggeri RM, Ovčariček PP, Campenni A, Treglia G, Deandreis D. Prevalence of thyroid dysfunction in patients with COVID-19: a systematic review. Clin Transl imaging. 2021;9:233–40.
20. Coutinho GM de M, Silva EC da, Campanharo CRV, Belasco AGS, Fonseca CD da, Barbosa DA. Urinary tract infection in patients with chronic kidney disease under conservative treatment. Rev Bras Enferm. 2021;75(03):e20210065.
21. Baxtiyorovich UJ, Alisherovna KM, Mamasoliyevna DN. Features of cognitive impairment in patients with chronic kidney disease at predialysis stages. World Bull Public Heal. 2023;22:49–54.
22. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Pang P, et al. Long COVID in patients with mild to moderate disease: do thyroid function and autoimmunity play a role? Endocr Pract. 2021;27(9):894–902.
23. Kalra S, Aggarwal S, Khandelwal D. Thyroid dysfunction and dysmetabolic syndrome: the need for enhanced thyrovigilance strategies. Int J Endocrinol. 2021;2021(1):9641846.